0QXH Stock Overview
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Epigenomics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.76 |
| 52 Week High | €1.50 |
| 52 Week Low | €0.76 |
| Beta | 1.18 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.02% |
| 5 Year Change | -98.76% |
| Change since IPO | -99.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QXH | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 2.7% |
| 1Y | n/a | -29.8% | 0.3% |
Return vs Industry: Insufficient data to determine how 0QXH performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0QXH performed against the UK Market.
Price Volatility
| 0QXH volatility | |
|---|---|
| 0QXH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QXH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0QXH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 18 | Noel Doheny | www.epigenomics.com |
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Epigenomics AG Fundamentals Summary
| 0QXH fundamental statistics | |
|---|---|
| Market cap | €2.60m |
| Earnings (TTM) | -€16.29m |
| Revenue (TTM) | €447.00k |
5.8x
P/S Ratio-0.2x
P/E RatioIs 0QXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QXH income statement (TTM) | |
|---|---|
| Revenue | €447.00k |
| Cost of Revenue | €105.00k |
| Gross Profit | €342.00k |
| Other Expenses | €16.63m |
| Earnings | -€16.29m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 09, 2023
| Earnings per share (EPS) | -3.82 |
| Gross Margin | 76.51% |
| Net Profit Margin | -3,644.52% |
| Debt/Equity Ratio | 0% |
How did 0QXH perform over the long term?
See historical performance and comparison